查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1930162

全球轉移性去勢抗性前列腺癌治療市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考察、未來預測（2026-2034）

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 278 Pages | 商品交期: 請詢問到貨日

價格

轉移性去勢抗性前列腺癌（mCRPC）治療市場成長因子

受晚期前列腺癌發病率上升和對有效治療方案需求不斷成長的推動，全球 mCRPC 治療市場正處於快速成長階段。該市場在2025年的估值為 210.4億美元，預計到2026年將成長至 290.8億美元，並在2034年達到 918.5億美元，預測期內年複合成長率（CAGR）為 15.46%。北美在2025年佔據市場主導地位，市場佔有率高達 87.63%。這得益於先進的醫療基礎設施、強有力的償付政策和廣泛的研發活動。

轉移性去勢抗性前列腺癌（mCRPC）是一種晚期前列腺癌，其腫瘤不再對雄性激素剝奪療法（ADT）完全敏感，並可轉移至骨骼、淋巴結、肝臟、肺部和腦部。這種癌症的侵襲性強，且發病率和死亡率高，因此迫切需要新的治療方法。根據世界癌症研究基金會統計，2022年全球將新增約 146萬例癌症病例，凸顯了對有效治療方法日益成長的需求。

市場驅動因素

市場成長主要受以下關鍵因素驅動：

  • 強大的藥物研發管線：製藥公司積極開發新一代雄性激素受體抑制劑、PARP 抑制劑和 CYP17 抑制劑，以應對治療抗藥性前列腺癌的挑戰。
  • 合作與夥伴關係：例如，2022年 7月，Merck & Co., Inc.與 Orion Corporation共同開發了 CYP11A1 抑制劑 opevesostat（MK-5684/ODM-208），用於治療轉移性去勢抗性前列腺癌（mCRPC）。
  • 治療進展：創新聯合療法的引進，例如 PARP 抑制劑和 AR 抑制劑的聯合療法，顯著改善了治療效果，並克服了對雄激素剝奪療法（ADT）的抗藥性。

市場限制與挑戰

儘管成長趨勢良好，但仍有幾個因素限制了市場擴張：

  • 荷爾蒙療法抗藥性：隨著時間的推移，前列腺癌細胞會適應雄性激素剝奪療法，這可能會降低傳統療法的療效。雄性激素受體路徑中的突變會進一步促進抗藥性的產生。
  • 不良反應：ZYTIGA（abiraterone）和enzalutamide等藥物與關節腫脹、低血鉀、水腫、腹瀉和心血管風險有關，這些都可能影響治療中斷和患者依從性。

市場機會

  • 診斷性放射治療的興起：將診斷影像與標靶治療相結合，可以實現個人化治療，在提高療效的同時最大限度地減少副作用。例如，Clarity Pharmaceuticals 於2023年 11月啟動了一項針對 mCRP 患者的64Cu/67Cu-SAR-bisPSMA 的I/IIa 期臨床試驗。
  • 聯合療法的日益普及：Pfizer公司於2024年 10月啟動的TALAPRO-2 試驗等研究表明，PARP 抑制劑和雄激素受體抑制劑聯合用藥可提高患者的存活率。

市場區隔分析

依藥物類別

  • 雄性激素受體抑制劑因其在抑制睪固酮介導的癌症生長方面的作用而佔據市場主導地位。
  • 由於新藥核准和合作關係的建立，促性腺激素釋放激素促效劑、促性腺激素釋放激素受體拮抗劑、微管抑制劑和PARP抑制劑預計將保持穩定成長。

依給藥途徑

  • 口服療法因其便利性以及患者依從性提高而佔據主導地位。
  • 腸外療法正透過創新性臨床試驗而發展，例如POINT Biopharma的Actinium-225（2024年4月上市）。

依療法

  • 荷爾蒙療法佔據主導地位，這得益於雄激素剝奪療法的廣泛應用以及醋酸阿比特龍等仿製藥的普及。
  • 標靶治療和免疫療法領域擴展，而化療的市場佔有率則因副作用而萎縮。

依通路

  • 由於醫療基礎設施完善，醫院藥局是主流管道。
  • 零售藥局和線上藥局因其便利性和可近性而不斷發展。

區域洞察

  • 北美：到2025年，北美市場規模將達到113.1億美元，這得益於美國和加拿大強大的醫療保健體系、完善的償付政策以及研發投入。
  • 歐洲：宣傳活動的加強和新型診斷工具的出現推動市場成長。例如，劍橋大學研發的一種新型 "超級檢測" （於2025年2月推出）能夠實現早期檢測。
  • 亞太地區：該地區將以13.6%的年複合成長率實現最快成長，主要受前列腺癌發病率上升和研究經費投入增加的推動。
  • 拉丁美洲、中東和非洲：由於政府主導的措施不斷加強以及癌症治療中心的擴建，預計該地區將實現溫和成長。

主要參與者趨勢

Pfizer Inc.、Johnson & Johnson Services, Inc.、Astellas Pharma Inc.、AbbVie Inc.、AstraZeneca等主要參與者憑藉其豐富的產品組合、監管審批、合作夥伴關係和新產品發布，引領著市場。主要趨勢包括：

  • 2023年8月：Johnson & Johnson的AKEEGA（niraparib + abiraterone）獲得FDA批准用於治療轉移性去勢抗性前列腺癌（mCRPC）。
  • 2023年6月：AstraZeneca的Lynparza獲準用於治療攜帶BRCA突變的患者。
  • 2022年12月：Novartis公司的Purvict獲得歐盟委員會批准，作為一種標靶放射性配體療法。

目錄

第1章 引言

第2章 執行摘要

第3章 市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機會
  • 市場趨勢

第4章 主要考察

  • 2025年主要國家及地區攝護腺癌盛行率
  • 主要公司產品線分析
  • 替代療法概述
  • 市場主要新創企業
  • 主要公司新產品發布
  • 主要產業發展動態（併購、合作等）
  • 新冠疫情的影響市場

第5章 全球轉移性去勢抗性前列腺癌治療市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依藥物類別劃分
    • 雄性激素受體抑制劑
    • 微管抑制劑
    • 促性腺激素釋放激素（GnRH）促效劑
    • 促性腺激素釋放激素（GnRH）受體拮抗劑
    • 其他
  • 市場分析、洞察與預測：依給藥途徑劃分
    • 口服
    • 腸外給藥
  • 市場分析、洞察與預測：依療法劃分
    • 化療
    • 荷爾蒙療法
    • 標靶治療治療
    • 免疫療法
  • 市場分析、洞察與預測：依通路劃分
    • 醫院藥房
    • 藥局及零售藥房
    • 線上藥房
  • 市場分析、洞察與預測：依地區劃分
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章 北美轉移性去勢抗性前列腺癌治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第7章 歐洲轉移性去勢抗性前列腺癌市場分析治療市場：洞察與預測（2021-2034）

  • 依國家劃分
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第8章 亞太地區轉移性去勢抗性前列腺癌治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 東南亞
    • 亞太其他地區

第9章 拉丁美洲轉移性去勢抗性前列腺癌治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章 中東與非洲轉移性去勢抗性前列腺癌治療市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • GCC國家
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市場佔有率分析（2025）
  • 公司簡介
    • Astellas Pharma Inc.
    • Pfizer Inc.
    • Johnson &Johnson Services, Inc.
    • Sanofi
    • Ferring Pharmaceuticals Inc.
    • Sumitomo Pharma Co., Ltd.（Myovant Sciences GmbH）
    • AbbVie Inc.
    • AstraZeneca
    • Tolmar, Inc.
    • Dendreon Pharmaceuticals LLC.
    • Bayer AG
Product Code: FBI112690

Growth Factors of metastatic castration-resistant prostate cancer (mCRPC) therapeutics Market

The global metastatic castration-resistant prostate cancer (mCRPC) therapeutics market is on a rapid growth trajectory, driven by the rising prevalence of advanced prostate cancer and the increasing demand for effective treatment options. The market was valued at USD 21.04 billion in 2025, projected to grow to USD 29.08 billion in 2026, and is expected to reach USD 91.85 billion by 2034, reflecting a CAGR of 15.46% during the forecast period. North America dominated the market in 2025, holding a 87.63% share, supported by advanced healthcare infrastructure, strong reimbursement policies, and extensive research and development activities.

mCRPC is an advanced form of prostate cancer where tumors no longer fully respond to androgen deprivation therapy (ADT) and may spread to bones, lymph nodes, liver, lungs, and the brain. The aggressive nature of this cancer, combined with high morbidity and mortality, creates an urgent need for novel therapeutics. According to the World Cancer Research Fund, approximately 1.46 million new cancer cases were registered worldwide in 2022, emphasizing the growing demand for effective treatments.

Market Drivers

The market growth is propelled by several key factors:

  • Robust drug pipelines: Pharmaceutical companies are actively developing next-generation androgen receptor inhibitors, PARP inhibitors, and CYP17 inhibitors to address the challenges of treatment-resistant prostate cancer.
  • Collaborations and partnerships: For instance, in July 2022, Merck & Co., Inc. and Orion Corporation co-developed opevesostat (MK-5684/ODM-208), a CYP11A1 inhibitor for mCRPC.
  • Therapeutic advancements: The launch of innovative combination therapies, such as pairing PARP inhibitors with AR inhibitors, significantly enhances treatment outcomes and combats resistance to ADT.

Market Restraints and Challenges

Despite the positive growth trajectory, several factors limit market expansion:

  • Resistance to hormonal therapy: Over time, prostate cancer cells may adapt to androgen deprivation, reducing the effectiveness of conventional treatments. Mutations in androgen receptor pathways further contribute to resistance.
  • Adverse side effects: Drugs like ZYTIGA (abiraterone) and enzalutamide are associated with joint swelling, hypokalemia, edema, diarrhea, and cardiovascular risks, which may lead to discontinuation and impact patient compliance.

Market Opportunities

  • Emergence of radiotheranostics: Combining diagnostic imaging with targeted therapy allows personalized treatment, improving efficacy while minimizing side effects. For example, in November 2023, Clarity Pharmaceuticals initiated a Phase I/IIa trial for 64Cu/67Cu-SAR-bisPSMA in mCRPC patients.
  • Growing adoption of combination therapies: Initiatives like Pfizer's TALAPRO-2 study in October 2024 show improved survival outcomes using PARP inhibitors with androgen receptor inhibitors.

Segmentation Analysis

By Drug Class

  • Androgen receptor inhibitors dominate the market due to their role in blocking testosterone-driven cancer growth.
  • GnRH agonists, GnRH receptor antagonists, microtubule inhibitors, and PARP inhibitors are projected to grow steadily due to new approvals and collaborations.

By Route of Administration

  • Oral therapies dominate due to convenience, patient adherence, and better compliance.
  • Parenteral therapies are growing through innovative clinical trials, such as Actinium-225 by POINT Biopharma (April 2024).

By Therapy

  • Hormonal therapy leads, supported by widespread adoption of androgen deprivation therapy and availability of generics like Abiraterone Acetate.
  • Targeted therapy and immunotherapy segments are expanding, while chemotherapy holds a smaller share due to side effects.

By Distribution Channel

  • Hospital pharmacies dominate, owing to advanced healthcare infrastructure.
  • Retail and online pharmacies are growing due to convenience and accessibility.

Regional Insights

  • North America: Market size USD 11.31 billion in 2025, supported by the U.S. and Canada's robust healthcare systems, reimbursement policies, and R&D.
  • Europe: Rising awareness campaigns and new diagnostic tools propel growth. For example, a new 'super test' developed in Cambridge (February 2025) enables early detection.
  • Asia Pacific: Fastest-growing region with a CAGR of 13.6%, fueled by increasing prostate cancer prevalence and research funding initiatives.
  • Latin America & Middle East & Africa: Moderate growth is anticipated, with increased government initiatives and expansion of cancer care centers.

Key Industry Players

Leading companies such as Pfizer Inc., Johnson & Johnson Services, Inc., Astellas Pharma Inc., AbbVie Inc., and AstraZeneca dominate the market through extensive product portfolios, regulatory approvals, collaborations, and new launches. Notable developments include:

  • August 2023: FDA approval of AKEEGA (niraparib + abiraterone) for mCRPC by Johnson & Johnson.
  • June 2023: AstraZeneca's Lynparza (olaparib) approved for patients with BRCA mutations.
  • December 2022: Novartis' Pluvicto approved by European Commission as targeted radioligand therapy.

Conclusion

The global metastatic castration-resistant prostate cancer therapeutics market is projected to grow from USD 21.04 billion in 2025 to USD 91.85 billion by 2034, at a CAGR of 15.46%. Market expansion is driven by the rising prevalence of advanced prostate cancer, robust R&D pipelines, innovative combination therapies, and emerging radiotheranostics. North America dominates, while Asia Pacific represents the fastest-growing region. Leading companies' strategic initiatives, product launches, and research collaborations are expected to sustain market growth and enhance treatment outcomes for mCRPC patients globally.

Segmentation By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa ( By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Prostate Cancer - by Key Countries/Regions, 2025
  • 4.2. Pipeline Analysis, by Key Players
  • 4.3. Overview of Alternative Therapies
  • 4.4. Key Start-ups in the Market
  • 4.5. New Product Launches, by Key Players
  • 4.6. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
  • 4.7. Impact of COVID-19 on the Market

5. Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Androgen Receptor Inhibitors
    • 5.1.2. Microtubule Inhibitors
    • 5.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 5.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 5.1.5. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Parenteral
  • 5.3. Market Analysis, Insights and Forecast - By Therapy
    • 5.3.1. Chemotherapy
    • 5.3.2. Hormonal Therapy
    • 5.3.3. Targeted therapy
    • 5.3.4. Immunotherapy
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacies
    • 5.4.2. Drug Stores & Retail Pharmacies
    • 5.4.3. Online Pharmacies
  • 5.5. Market Analysis, Insights and Forecast - Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Androgen Receptor Inhibitors
    • 6.1.2. Microtubule Inhibitors
    • 6.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 6.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 6.1.5. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Parenteral
  • 6.3. Market Analysis, Insights and Forecast - By Therapy
    • 6.3.1. Chemotherapy
    • 6.3.2. Hormonal Therapy
    • 6.3.3. Targeted therapy
    • 6.3.4. Immunotherapy
  • 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.4.1. Hospital Pharmacies
    • 6.4.2. Drug Stores & Retail Pharmacies
    • 6.4.3. Online Pharmacies
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Androgen Receptor Inhibitors
    • 7.1.2. Microtubule Inhibitors
    • 7.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 7.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 7.1.5. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. Market Analysis, Insights and Forecast - By Therapy
    • 7.3.1. Chemotherapy
    • 7.3.2. Hormonal Therapy
    • 7.3.3. Targeted therapy
    • 7.3.4. Immunotherapy
  • 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Drug Stores & Retail Pharmacies
    • 7.4.3. Online Pharmacies
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.5.1. Germany
    • 7.5.2. U.K.
    • 7.5.3. France
    • 7.5.4. Italy
    • 7.5.5. Spain
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Androgen Receptor Inhibitors
    • 8.1.2. Microtubule Inhibitors
    • 8.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 8.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 8.1.5. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Parenteral
  • 8.3. Market Analysis, Insights and Forecast - By Therapy
    • 8.3.1. Chemotherapy
    • 8.3.2. Hormonal Therapy
    • 8.3.3. Targeted therapy
    • 8.3.4. Immunotherapy
  • 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.4.1. Hospital Pharmacies
    • 8.4.2. Drug Stores & Retail Pharmacies
    • 8.4.3. Online Pharmacies
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.5.1. China
    • 8.5.2. Japan
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Androgen Receptor Inhibitors
    • 9.1.2. Microtubule Inhibitors
    • 9.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 9.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 9.1.5. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Parenteral
  • 9.3. Market Analysis, Insights and Forecast - By Therapy
    • 9.3.1. Chemotherapy
    • 9.3.2. Hormonal Therapy
    • 9.3.3. Targeted therapy
    • 9.3.4. Immunotherapy
  • 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Drug Stores & Retail Pharmacies
    • 9.4.3. Online Pharmacies
  • 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Androgen Receptor Inhibitors
    • 10.1.2. Microtubule Inhibitors
    • 10.1.3. Gonadotropin Releasing Hormone (GnRH) Agonist
    • 10.1.4. Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
    • 10.1.5. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Parenteral
  • 10.3. Market Analysis, Insights and Forecast - By Therapy
    • 10.3.1. Chemotherapy
    • 10.3.2. Hormonal Therapy
    • 10.3.3. Targeted therapy
    • 10.3.4. Immunotherapy
  • 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.4.1. Hospital Pharmacies
    • 10.4.2. Drug Stores & Retail Pharmacies
    • 10.4.3. Online Pharmacies
  • 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.5.1. GCC
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Astellas Pharma Inc.
      • 11.2.1.1. Overview
      • 11.2.1.2. Products
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Pfizer Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Johnson & Johnson Services, Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. Ferring Pharmaceuticals Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Sumitomo Pharma Co., Ltd. (Myovant Sciences GmbH)
      • 11.2.6.1. Overview
      • 11.2.6.2. Products
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. AbbVie Inc.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. AstraZeneca
      • 11.2.8.1. Overview
      • 11.2.8.2. Products
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Tolmar, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. Dendreon Pharmaceuticals LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Products
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)
    • 11.2.11. Bayer AG
      • 11.2.11.1. Overview
      • 11.2.11.2. Products
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 14: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 15: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 16: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 18: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 19: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 20: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 23: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 24: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 25: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 28: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Therapy, 2021-2034
  • Table 29: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, by Distribution Channel 2021-2034
  • Table 30: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025 & 2034
  • Figure 5: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 6: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 12: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 13: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 14: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 15: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country, 2025
  • Figure 17: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 22: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 23: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 24: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 25: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 32: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 33: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion),by Distribution Channel, 2025 & 2034
  • Figure 34: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 35: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 42: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 43: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 44: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 45: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Therapy, 2025 & 2034
  • Figure 52: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Therapy, 2025
  • Figure 53: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 54: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), by Distribution Channel, 2025
  • Figure 55: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Value Share (%), By Country/ Sub-region, 2025

Figure 57: Global Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Share (%), By Company, 2025